HomeInsightsResults

Medicamen Biotech Ltd Quarterly Result

Medicamen Biotech Ltd Quarterly Result

stocks purchased

₹ 0.5 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

10.5 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Medicamen Biotech Ltd

NSE: MEDICAMEQ

Net Profit

₹ 0.9

Last updated on: Nov 23, 2024

Key Highlights

  • The revenue of Medicamen Biotech Ltd for the Sep '24 is ₹ 45.03 crore as compare to the Jun '24 revenue of ₹ 43.63 crore. This represent the growth of 3.208796%.
  • The ebitda of Medicamen Biotech Ltd for the Sep '24 is ₹ 5.6 crore as compare to the Jun '24 ebitda of ₹ 4.03 crore. This represent the growth of 38.957806%.
  • The net profit of Medicamen Biotech Ltd for the Sep '24 is ₹ 0.9 crore as compare to the Jun '24 net profit of ₹ 0.8 crore. This represent the growth of 12.499995%.

Results Analysis

Market Price of Medicamen Biotech Ltd

1M

1Y

3Y

5Y

Monitoring Medicamen Biotech Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024448.05
21 Nov 2024431.4
19 Nov 2024449.1
18 Nov 2024463.2
14 Nov 2024450.8
13 Nov 2024456.65
12 Nov 2024481.1
11 Nov 2024489.95
08 Nov 2024506.7
07 Nov 2024517.45

Historical Revenue of Medicamen Biotech Ltd

No data available

* All values are in crore

Historical EBITDA of Medicamen Biotech Ltd

No data available

* All values are in crore

Historical Net Profit of Medicamen Biotech Ltd

No data available

* All values are in crore

Medicamen Biotech Ltd News Hub

News

Medicamen Biotech declare Quarterly Result

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 14 Novem...

Read more

08 Nov 202412:28

News

Medicamen Biotech to conduct AGM

Medicamen Biotech announced that the Annual General Meeting (AGM) of the company will be h...

Read more

13 Sep 202411:43

News

Medicamen Biotech to conduct board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 13 Augus...

Read more

12 Aug 202410:31

News

Board of Medicamen Biotech recommends Final Dividend

Medicamen Biotech announced that the Board of Directors of the Company at its meeting held...

Read more

29 May 202417:32

News

Medicamen Biotech schedules board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 29 May 2...

Read more

25 May 202415:28

News

Medicamen Biotech to conduct board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 12 Febru...

Read more

06 Feb 202414:01

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Medicamen Biotech Ltd Quarterly Result

What is the EPS of Medicamen Biotech Ltd stock?

The Earnings Per Share (EPS) of Medicamen Biotech Ltd is 5.77. An EPS is the amount of net income attributed to each share of a common stock.

How is Medicamen Biotech Ltd EPS calculated?

The EPS of Medicamen Biotech Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Medicamen Biotech Ltd report its EPS?

Medicamen Biotech Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Medicamen Biotech Ltd EPS?

Factors that influence the EPS of Medicamen Biotech Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Medicamen Biotech Ltd EPS growth indicate future performance?

Yes, consistent growth in Medicamen Biotech Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*